Literature DB >> 25451562

Tumor necrosis factor-related apoptosis-inducing ligand in vascular inflammation and atherosclerosis: a protector or culprit?

Wen Cheng1, Yuxia Zhao2, Shuangxi Wang1, Fan Jiang3.   

Abstract

In addition to inducing tumor cell apoptosis, tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) shows broad biological functions both in vitro and in vivo. TRAIL gene deletion enhanced atherogenesis in hyperlipidemic mice, supporting that endogenous TRAIL has protective actions in maintaining blood vessel homeostasis and repressing atherosclerosis. The mechanisms of this beneficial effect are not understood. It remains to be determined whether the athero-protective action of TRAIL is via direct impacts on residential vascular cells or indirectly by modulating systemic immune functions. However, in vitro experiments indicate that excessive TRAIL may stimulate endothelial cell apoptosis, smooth muscle proliferation and migration, and inflammatory responses. Moreover, TRAIL can stimulate lipid uptake and foam cell formation in cultured macrophages. Here we provide a critical review on the potential relationships between TRAIL and atherosclerosis. We propose that increased TRAIL production may also have potential detrimental effects on vascular inflammation and atherosclerosis. Further in vivo experiments are warranted to elucidate the effects of exogenous TRAIL on atherogenesis.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Atherosclerosis; Death receptors; Immune response; TRAIL; Vascular inflammation

Mesh:

Substances:

Year:  2014        PMID: 25451562     DOI: 10.1016/j.vph.2014.10.004

Source DB:  PubMed          Journal:  Vascul Pharmacol        ISSN: 1537-1891            Impact factor:   5.773


  9 in total

1.  Soluble TNF-related apoptosis induced ligand (sTRAIL) is augmented by Post-Conditioning and correlates to infarct size and left ventricle dysfunction in STEMI patients: a substudy from a randomized clinical trial.

Authors:  André Luz; Mário Santos; Rui Magalhães; José Carlos Oliveira; Ana Pacheco; João Silveira; Sofia Cabral; Severo Torres; Adelino F Leite-Moreira; Henrique Carvalho
Journal:  Heart Vessels       Date:  2016-05-26       Impact factor: 2.037

Review 2.  TNF-related apoptosis inducing ligand in ocular cancers and ocular diabetic complications.

Authors:  Paolo Perri; Giorgio Zauli; Arianna Gonelli; Daniela Milani; Claudio Celeghini; Giuseppe Lamberti; Paola Secchiero
Journal:  Biomed Res Int       Date:  2015-03-05       Impact factor: 3.411

Review 3.  Clinical perspectives of TRAIL: insights into central nervous system disorders.

Authors:  Veronica Tisato; Arianna Gonelli; Rebecca Voltan; Paola Secchiero; Giorgio Zauli
Journal:  Cell Mol Life Sci       Date:  2016-02-24       Impact factor: 9.261

4.  TRAIL (TNF-related apoptosis-inducing ligand) inhibits human adipocyte differentiation via caspase-mediated downregulation of adipogenic transcription factors.

Authors:  Verena Zoller; Jan-Bernd Funcke; Michaela Keuper; Muad Abd El Hay; Klaus-Michael Debatin; Martin Wabitsch; Pamela Fischer-Posovszky
Journal:  Cell Death Dis       Date:  2016-10-13       Impact factor: 8.469

Review 5.  Traditional Chinese Medicine Protects against Cytokine Production as the Potential Immunosuppressive Agents in Atherosclerosis.

Authors:  Yan Ren; Wei Qiao; Dongliang Fu; Zhiwei Han; Wei Liu; Weijie Ye; Zunjing Liu
Journal:  J Immunol Res       Date:  2017-09-06       Impact factor: 4.818

6.  Relation Between Plasma Proteomics Analysis and Major Adverse Cardiovascular Events in Patients With Stable Coronary Artery Disease.

Authors:  Mihaela Ioana Dregoesc; Adrian Bogdan Ţigu; Siroon Bekkering; Charlotte D C C van der Heijden; Sorana Daniela Bolboacǎ; Leo A B Joosten; Frank L J Visseren; Mihai G Netea; Niels P Riksen; Adrian Corneliu Iancu
Journal:  Front Cardiovasc Med       Date:  2022-02-08

Review 7.  Roles and Clinical Applications of OPG and TRAIL as Biomarkers in Cardiovascular Disease.

Authors:  Stella Bernardi; Fleur Bossi; Barbara Toffoli; Bruno Fabris
Journal:  Biomed Res Int       Date:  2016-04-21       Impact factor: 3.411

8.  Soluble TRAIL Concentration in Serum Is Elevated in People with Hypercholesterolemia.

Authors:  Wen Cheng; Fangfang Liu; Zhe Wang; Yun Zhang; Yu-Xia Zhao; Qunye Zhang; Fan Jiang
Journal:  PLoS One       Date:  2015-12-03       Impact factor: 3.240

9.  Low Circulating TRAIL Levels Are Associated with Increase of Resistin and Lipocalin-2/ngal Adipokines in Postmenopausal Women.

Authors:  Veronica Tisato; Paola Secchiero; Gloria Bonaccorsi; Carlo Bergamini; Pantaleo Greco; Giorgio Zauli; Carlo Cervellati
Journal:  Mediators Inflamm       Date:  2017-09-05       Impact factor: 4.711

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.